Are SSRIs Really More Effective for Anxious Depression?

References

• Fava M, Uebelacker L, Alpert J, Nierenberg A, Pava J, Rosenbaum J: Major depressive subtypes and treatment response. Biol Psych 1997; 42(7):568–576.
   PubMed Web of Science ®Google Scholar
• Fawcett J, Barkin R: A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psych 1998; 59(3):123–127.
   Google Scholar
• Lydiard R, Brawman-Mintzer O: Anxious depression. J Clin Psych 1998; 59(Suppl 18):10–17.
   Google Scholar
• Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 134:382–389.
   Google Scholar
• Covi L, Rickels K, Lipman O: Effects of psychotropic agents on primary depression. Psychopharm Bull 1981; 17:100–101.
   Google Scholar
• Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.
   PubMed Web of Science ®Google Scholar
• Montgomery S, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–38.
   PubMed Web of Science ®Google Scholar
• Diagnostic and statistical manual for mental disorders; DSM-III. Washington, DC: American Psychiatric Association; 1980.
   Google Scholar
• Diagnostic and statistical manual for mental disorders: DSM-III-R, 3rd ed. Revised. Washington, DC: American Psychiatric Asso-ciation; 1989.
   Google Scholar
• Diagnostic and statistical manual for mental disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Feighner J, Gardner E, Johnston J, Batey S, Khayrallah M, Ascher J, Lineberry C: Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psych 1991; 52: 329–335.
   Google Scholar
• Kavoussi R, Segraves R, Hughes A, Ascher J, Johnston J: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psych 1997; 58: 532–537.
   Google Scholar
• Coleman C, Cunningham L, Foster V, Batey S, Donahue R, Houser T, Ascher J: Sexual dysfunction associated with the treat-ment of depression: A placebo-controlled comparison of bupro-pion sustained release and sertraline treatment. Annals of Clin Psych 1999; 11(4):205–215.
   Google Scholar
• Croft H, Settle E, Houser T, Batey S, Donahue R, Ascher J: A pla-cebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 12:643–658.
   Google Scholar
• Trivedi M, Rush A, Carmody T, Donahue R, Bolden-Watson C, Houser T, Metz A: Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psych 2001; 62:776–781.
   Google Scholar
• Rush A, Batey S, Donahue R, Ascher J, Carmody T, Metz A: Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Aff Dis 2001; 64:81–87.
   Google Scholar
• Rush A, Trivedi M, Carmody T, Donahue R, Houser T, Bolden- Watson C, Batey S, Ascher J, Metz A: Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharm 2001; 25:131–138.
   Google Scholar
• Weihs K, Settle E, Batey S, Houser T, Donahue R, Ascher J: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psych 2000; 61:196–202.
   Google Scholar
• Nieuwstraten C, Dolovich L: Bupropion versus selective serotoninreuptake inhibitors for treatment of depression. Ann Pharmacother 2001; 35(12):1608–1613.
   Google Scholar
• Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen J, and the Nordic Antidepressant Study Group: Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999; 14:329–337.
   Google Scholar
• Benkert O, Szegedi A, Kohnen R: Mirtazapine compared with paroxetine in major depression. J Clin Psych 2000; 61: 656–663.
   Google Scholar
• Schatzberg A, Kremer C, Rodrigues H, Murphy G, and The Mir-tazapine vs. Paroxetine Study Group: Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressedpatients. Am J Geriatr Psychiatry 2002; 10(5):541–555.
   Google Scholar
• Wheatley D, Moffaert M, Timmerman L: Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psych 1998; 59:306–312.
   Google Scholar
• Smith W, Glaudin V. Panagides J, Gilvary E: Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharm Bull 1990; 26(2):191–196.
   Google Scholar
• Halikas J: Org 3770 (mirtazapine) versus trazodone: A placebo-controlled trial in depressed elderly patients. Human Psychop-harm 1995; 10:S125–S133.
   Google Scholar
• Bremner J: A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psych 1995; 56: 519–525.
   Google Scholar
• Dunbar G, Cohn J, Fabre L, Feighner J, Fieve R, Mendels J, Shrivastava R: A comparison of paroxetine, imipramine and pla-cebo in depressed out-patients. Br J Psych 1991; 159:394–398.
   PubMed Web of Science ®Google Scholar
• Marchesi C, Ceccerininelli A, Rossi A, Maggini C: Is anxious-agitated major depression responsive to fluoxetine? A double - blind comparison with amitriptyline. Pharmacopsych 1998; 31(6): 216–221.
   Google Scholar
• Versiani M, Ontiveros A, Mazzotti G, Ospina J, Davila J, Mata S. Pacheco A, Plewes J, Tamura R, Palacios M: Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int Clin Psychopharm 1999; 14(6) :321–327.
   Google Scholar
• Fava M, Rosenbaum R, Hoog S, Tepner R, Kopp J, Nilsson M: Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Dis 2000; 59:119–126.
   PubMed Web of Science ®Google Scholar
• Stahl S: Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psych 2000; 48:894–901.
   PubMed Web of Science ®Google Scholar
• Branconnier, Cole J, Ghazvinian S, Spera K, Oxenkrug G, Bass J: Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psych 1983; 44(5):130–133.
   Google Scholar
• Feighner J, Hendrickson G, Miller L, Stern W: Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharm 1986; 6(1): 27–32.
   Google Scholar
• Mendels J, Amin A, Chouinard G, Cooper A, Miles J, Remick R, Saxena B, Secunda S, Singh A: A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychopharm 1983; 44:118–120.
   Google Scholar
• Rickets K, Schweizer E, Clary C: Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psych 1994; 164:802–805.
   Google Scholar
• Fontaine R, Ontiveros A, Elie R, Kensler T, Roberts D, Kaplita S, Ecker J, Faludi G: A double-blind comparison of nefazodone, imipramine and placebo in major depression. J Clin Psych 1994; 55:234–241.
   Google Scholar
• Fawcett J, Marcus R, Anton S, O'Brien K, Schwiderski U: Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psych 1995; 56\(suppl 6): 37–42.
   Google Scholar
• Baldwin D, Hawley C, Abed R, Maragakis B, Cox J, Buckingham S, Pover G, Ascher A: A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psych 1996; 57\(suppl 2): 46–52.
   Google Scholar
• Cunningham L, Borison R, Carman J, Chouinard G, Crowder J, Diamond B, Fischer D, Hearst E: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharm 1994; 14(2):99–106.
   Google Scholar
• Silverstone P. Ravindran A: Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depres-sion and anxiety. J Clin Psych 1999; 60:22–28.
   Google Scholar
• Ballus C, Quiros G, Flores T, Torre J, Palao D, Rojo L, Guteirrez M, Casais L, Riesgo Y:The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharm 2000; 15(1): 43–48.
   Google Scholar
• Davidson J, Meoni P. Haudiquet V, Cantillon M, Hackett D: Achieving remission with Venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depression and Anxiety 2002; 16:4–13.
   PubMed Web of Science ®Google Scholar
• Overall J, Hollister L, Johnson M, Pennington V: Nosology of depression and differential response to drugs. J Am Med Assoc 1966; 195:162–164.
   Google Scholar
• VanValkenburg C, Akiskal H, Puzantian V, Rosenthal T: Anxi-ous depressions: Clinical, family history, and naturalistic outcome: Comparisons with panic and major depressive disorders. J Aff Dis 1984; 6(1):67–82.
   Google Scholar
• Meller M, Kathol R, Samuelson S, Gehris T: CRH challenge test in anxious depression. Biol Psych 1995; 37(6):376–382.
   Google Scholar
• Rao M, Vartzopoulos D, Fels K: Thyroid function in anxious and depressed patients.Pharmacopsychiatry 1989; 22(2): 66–70.
   Google Scholar